About 44% of cancer patients may be eligible for an FDA-approved checkpoint inhibitor drug, yet approximately 13% will respond to them, researchers say.
Reuters Health Information
About 44% of cancer patients may be eligible for an FDA-approved checkpoint inhibitor drug, yet approximately 13% will respond to them, researchers say.
Reuters Health Information
